Stopping treatment for kidney cancer based on PET/CT results
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced or metastatic kidney cancer (stage IV).
- Your cancer is considered favorable or intermediate risk (not poor risk).
- You have been on your first treatment (a combination of immunotherapy and a targeted therapy pill) for at least 12 months and it has not caused side effects that force you to stop.
- A PET/CT scan within the last 24 months shows your cancer has either completely disappeared or significantly shrunk.
- You are able to undergo PET/CT scans and take oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial is testing a new imaging agent called 18F-NY104 to see if it can help doctors see kidney cancer tumors on a PET/CT scan. If you have known or suspected kidney cancer that has spread or come back, this study may help find out if the tracer works for you.
This trial tests whether a special type of imaging scan (CD70-targeted PET/CT) can help doctors safely pause treatment in patients with advanced kidney cancer who respond well to standard immunotherapy and targeted therapy. The goal is to reduce unnecessary treatment while keeping the cancer controlled.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This study tests what happens when people with advanced kidney cancer switch their treatment after the first one stops working. It looks at two different switch options: going from a TKI to a TKI plus immunotherapy, or from a TKI plus immunotherapy back to a TKI.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.